Segall Bryant & Hamill LLC Boosts Position in Repligen Corporation $RGEN

Segall Bryant & Hamill LLC raised its position in Repligen Corporation (NASDAQ:RGEN) by 5.5% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 155,025 shares of the biotechnology company’s stock after acquiring an additional 8,045 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Repligen were worth $18,265,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Measured Wealth Private Client Group LLC bought a new stake in Repligen during the third quarter valued at approximately $29,000. Bayforest Capital Ltd purchased a new stake in Repligen during the fourth quarter valued at approximately $32,000. Rachor Investment Advisory Services LLC bought a new position in Repligen in the fourth quarter worth approximately $33,000. Los Angeles Capital Management LLC bought a new position in Repligen in the fourth quarter worth approximately $36,000. Finally, Farther Finance Advisors LLC boosted its stake in shares of Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 128 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.60% of the company’s stock.

Repligen Price Performance

NASDAQ:RGEN opened at $141.01 on Friday. The business’s 50-day moving average is $134.66 and its 200 day moving average is $131.60. Repligen Corporation has a 12 month low of $100.99 and a 12 month high of $175.77. The company has a market capitalization of $7.96 billion, a P/E ratio of 193.16, a P/E/G ratio of 2.62 and a beta of 1.06. The company has a current ratio of 9.05, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business had revenue of $204.13 million during the quarter, compared to analysts’ expectations of $201.59 million. During the same quarter last year, the business posted $0.26 EPS. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, equities research analysts forecast that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on RGEN shares. Canaccord Genuity Group cut their price target on Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a report on Monday, April 20th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $142.00 price objective on shares of Repligen in a research note on Tuesday, May 5th. Royal Bank Of Canada began coverage on Repligen in a research note on Thursday, May 14th. They set an “outperform” rating and a $160.00 price objective for the company. Rothschild & Co Redburn set a $160.00 target price on shares of Repligen and gave the stock a “buy” rating in a report on Friday, April 17th. Finally, Wells Fargo & Company increased their target price on shares of Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $166.43.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.